The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment
Yi Liu,Mingyan Ju,Zihan Wang,Jiaci Li,Chenyi Shao,Ting Fu,Yaqing Jing,Yuxia Zhao,Zhe Lv,Guang Li
DOI: https://doi.org/10.1016/j.biopha.2020.110235
2020-08-01
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and deformity. Mesenchymal stem cells (MSCs) infusion can improve bone performance mainly due to their differentiation into osteoblasts in OI therapy. The osteoinductive activity of NELL1 have benefited various bone defect and osteoporotic models by promoting bone formation. The present study investigated the efficacy of combined use of NELL1 and adipose-derived mesenchymal stem cells (ADSCs) in OI treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Lentiviral vector carrying mouse <em>Nell1</em> gene was constructed and lentivirus were used to infect ADSCs. The osteogenic capacity of MC3T3-E1 and ADSCs stimulated by recombinant mouse NELL1 protein (rmNELL1) and <em>Nell1</em> gene genetically modified ADSCs (lenti-Nell1-ADSCs) were estimated by real-time quantitative PCR. Thirty adult male OI type I mice with single <em>Col1a1</em> gene knockout were randomly divided into five groups and received intravenously injected PBS, rmNELL1 (1.25 mg/Kg), ADSCs (2 × 10<sup>5</sup> cells per mice), rmNELL1 (1.25 mg/Kg) combined with ADSCs (2 × 10<sup>5</sup> cells per mice), or lenti-Nell1-ADSCs (2 × 10<sup>5</sup> cells per mice) respectively. Six wildtype (WT) mice served as positive control. Bone formation was examined after 4 weeks using micro-CT, histological and immunohistochemical methods.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Three osteoblast related genes of MC3T3-E1 and ADSCs were significantly up-regulated by rmNELL1 <em>in vitro</em>. Lenti-Nell1-ADSCs showed greatly enhanced osteogenic differentiation capacity. The infused lenti-Nell1-ADSCs could migrate to femur and differentiate into ALPL-positive cells. Systemic administration of rmNELL1 combined with ADSCs or lenti-Nell1-ADSCs markedly improved the femoral microstructure and promoted bone formation through increasing the ALPL and osteocalcin (OCN) expression, much better than mice that received single rmNELL1 or ADSCs. And <em>Nell1</em> gene engineered ADSCs achieved slightly better outcomes than that of combinative use of rmNELL1 and ADSCs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>NELL1 and ADSCs exhibited synergistic effect on stimulating bone formation of OI mice, which might provide an alternative strategy in OI treatment. Compared with dose escalation or multiple administration of rmNELL1, lentivirus-mediated long term expression of NELL1 might be more feasible and convenient. However, further studies are needed to confirm the safety and optimize the therapeutic regime.</p>
pharmacology & pharmacy,medicine, research & experimental